Savara Inc.
NASDAQ: SVRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Pauls
- Employees
- 59
- Headquarters
- Langhorne, United States
- IPO year
- 2017
- Market cap
- $1.2B
- Website
- https://www.savarapharma.com
Loading SVRA…
Loading profile data…Frequently asked questions about SVRA
What does Savara Inc. (SVRA) do?
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune p...
Where does SVRA trade?
Savara Inc. (SVRA) trades on the NASDAQ Global Select.
What sector is SVRA in?
Savara Inc. (SVRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Savara Inc.?
Matthew Pauls is the chief executive officer of Savara Inc. (SVRA).
Where is Savara Inc. headquartered?
Savara Inc. is headquartered in United States.
Does SVRA pay a dividend?
Savara Inc. (SVRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SVRA go public?
Savara Inc. (SVRA) completed its initial public offering in 2017.